Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Maze Therapeutics, Inc.NASDAQ: MAZE
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 13.6% from a year ago
Common stock stood at $50K at the end of Q1 FY2026, up 13.6% from a year earlier and up 2.0% from the prior quarter. Over 3 fiscal years it compounded at +32.6% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +13.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 49K USD
- Year-over-year change
- +2350.0%
- 3-year CAGR
- +32.6%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49K | +2350.0% |
| FY2024 | 2024-12-31 | 2K | -90.9% |
| FY2023 | 2023-12-31 | 22K | +4.8% |
| FY2022 | 2022-12-31 | 21K | — |
Common Stock vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +13.6% is the 2nd highest of 6, against a peer median of +4.4%.
- Common stock amounts to 0.0% of total assets for MAZE, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | €1.93M EUR | +101.8% | +66.2% | 0.8% | |
| Jun 2026 | $82K USD | +5.1% | +3.6% | 0.0% | |
| Mar 2026 | $50K USD | +13.6% | +32.6% | 0.0% | |
SEPNSepterna, Inc. | Sep 2026 | $47K USD | +4.4% | +146.6% | 0.0% |
| Mar 2026 | $25K USD | +4.2% | +6.3% | 0.0% | |
| Sep 2026 | $9K USD | +0.0% | +14.5% | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
BIOABioAge Labs, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding MAZE) | — | +4.4% | +14.5% | 0.0% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.